Source:http://linkedlifedata.com/resource/pubmed/id/19464304
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10-11
|
pubmed:dateCreated |
2009-7-27
|
pubmed:abstractText |
The applicability of LC-MS/MS in precursor ion scan mode for the detection of urinary stanozolol metabolites has been studied. The product ion at m/z 81 has been selected as specific for stanozolol metabolites without a modification in A- or N-rings and the product ions at m/z 97 and 145 for the metabolites hydroxylated in the N-ring and 4-hydroxy-stanozolol metabolites, respectively. Under these conditions, the parent drug and up to 15 metabolites were found in a positive doping test sample. The study of a sample from a chimeric uPA-SCID mouse collected after the administration of stanozolol revealed the presence of 4 additional metabolites. The information obtained from the product ion spectra was used to develop a SRM method for the detection of 19 compounds. This SRM method was applied to several doping positive samples. All the metabolites were detected in both the uPA-SCID mouse sample and positive human samples and were not detected in none of the blank samples tested; confirming the metabolic nature of all the detected compounds. In addition, the application of the SRM method to a single human excretion study revealed that one of the metabolites (4xi,16xi-dihydroxy-stanozolol) could be detected in negative ionization mode for a longer period than those commonly used in the screening for stanozolol misuse (3'-hydroxy-stanozolol, 16beta-hydroxy-stanozolol and 4beta-hydroxy-stanozolol) in doping analysis. The application of the developed approach to several positive doping samples confirmed the usefulness of this metabolite for the screening of stanozolol misuse. Finally, a tentative structure for each detected metabolite has been proposed based on the product ion spectra measured with accurate masses using UPLC-QTOF MS.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
1878-5867
|
pubmed:author |
pubmed-author:DelbekeFrans TFT,
pubmed-author:DeventerKoenK,
pubmed-author:GrimaltSusanaS,
pubmed-author:HernándezFelixF,
pubmed-author:Leroux-RoelsGeertG,
pubmed-author:LootensLeenL,
pubmed-author:MeulemanPhilipP,
pubmed-author:PozoOscar JOJ,
pubmed-author:SanchoJuan VJV,
pubmed-author:Van EenooPeterP
|
pubmed:issnType |
Electronic
|
pubmed:volume |
74
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
837-52
|
pubmed:meshHeading |
pubmed-meshheading:19464304-Adult,
pubmed-meshheading:19464304-Anabolic Agents,
pubmed-meshheading:19464304-Animals,
pubmed-meshheading:19464304-Chromatography, Liquid,
pubmed-meshheading:19464304-Doping in Sports,
pubmed-meshheading:19464304-Humans,
pubmed-meshheading:19464304-Male,
pubmed-meshheading:19464304-Mice,
pubmed-meshheading:19464304-Mice, Transgenic,
pubmed-meshheading:19464304-Stanozolol,
pubmed-meshheading:19464304-Tandem Mass Spectrometry
|
pubmed:year |
2009
|
pubmed:articleTitle |
Detection and structural investigation of metabolites of stanozolol in human urine by liquid chromatography tandem mass spectrometry.
|
pubmed:affiliation |
DoCoLab, UGent, Department of Clinical Chemistry, Microbiology and Immunology, Technologiepark 30, B-9052 Zwijnaarde, Belgium. oscar.pozomendoza@ugent.be
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|